Montelukast: results and prospects for applications in pediatric practice
https://doi.org/10.21518/ms2024-026
Abstract
The Centers for Disease Control and Prevention reports that more than 4 million children have been diagnosed with asthma. Currently, there is no treatment that could prevent the development of asthma or change its natural course over long-term follow-up. However, the disease can be controlled using treatments used in clinical practice. For persistent asthma in children aged 5 years and younger, low doses of inhaled glucocorticosteroids are recommended, as well as the administration of montelukast, a leukotriene receptor antagonist. In addition, montelukast is prescribed to patients with allergic rhinitis as an alternative to or in combination with oral antihistamines or nasal corticosteroids. Leukotrienes are lipid mediators that play a key role in acute and chronic inflammation and allergic diseases. They exhibit their biological effects by binding to specific G-protein-coupled receptors. Each subtype of the leukotriene receptor has unique functions and expression patterns. Leukotrienes play an important role in various allergic diseases, including bronchial asthma and allergic rhinitis. Montelukast is a cysteinyl leukotriene receptor-1 antagonist widely used to suppress the inflammatory response in asthma and allergic rhinitis. This review briefly summarizes the biology of leukotrienes and their receptors, recent developments in the field of antileukotriene drugs and the prospects for their different therapeutic applications. The role of antileukotriene drugs and key indications for the use of montelukast in the complex therapy of asthma and allergic rhinitis in children have been determined.
About the Authors
Yu. L. Mizernitskiy
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Yury L. Mizernitskiy, Dr. Sci. (Med.), Professor, Honored Health Worker of the Russian Federation, Head of the Department of Chronic Inflammatory and Allergic Lung Diseases, Professor of the Department of Innovative Paediatrics and Paediatric Surgery
2, Taldomskaya St., Moscow, 125412
A. I. Petrova
Chita State Medical Academy
Russian Federation
Russian Federation
Anzhelika I. Petrova, Cand. Sci. (Med.), Assistant of the Pediatrics Department
39a, Gorky St., Chita, 672000
References
1. Altaş U, Altaş ZM, Öz F, Özkars MY. Evaluation of Neuropsychiatric Effects of Montelukast-L evocetirizine Combination Therapy in Children with Asthma and Allergic Rhinitis. Children (Basel). 2023;10(8):1301. https://doi.org/10.3390/children10081301.
2. Мизерницкий ЮЛ, Сулайманов ША. Антилейкотриеновые препараты в современной педиатрической практике. Российский вестник перинатологии и педиатрии. 2019;64(4):128–132. https://doi.org/10.21508/1027-4065-2019-64-4-128-132. Mizernitsky YuL, Sulaimanov ShA. Anti-leukotriene drugs in modern pediatric practice. Russian Bulletin of Perinatology and Pediatrics. 2019;64(4):128–132. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-4-128-132.
3. Фурман ЕГ, Грымова НН, Санакоева ЛП, Крылова ОА, Мазунина ЕС. Оценка риска развития бронхиальной астмы у детей раннего возраста с помощью опросника «Asthma Prediction Tool». Российский вестник перинатологии и педиатрии. 2018;63(1):34–39. https://doi.org/10.21508/1027-4065-2018-63-1-34-39. Furman EG, Grymova NN, Sanakoeva LP, Krylova OA, Mazunina ES. Risk assessment for the bronchial asthma development in infants using a Russian language version of questionnaire “Asthma Prediction Tool”. Russian Bulletin of Perinatology and Pediatrics. 2018;63(1):34–39. (In Russ.) https://doi.org/10.21508/1027-4065-2018-63-1-34-39.
4. Сулайманов ША, Муратова ЖК. Эпидемиология и коморбидность аллергических заболеваний у детей. В: Мизерницкий ЮЛ (ред.). Пульмонология детского возраста: проблемы и решения. Вып. 16. М.: Медпрактика-М; 2016. С. 179–181.
5. Varshney J, Varshney H. Allergic Rhinitis: an Overview. Indian J Otolaryngol Head Neck Surg. 2015;67(2):143–149. https://doi.org/10.1007/s12070-015-0828-5.
6. Li Q, Zhang X, Feng Q, Zhou H, Ma C, Lin C et al. Common Allergens and Immune Responses Associated with Allergic Rhinitis in China. J Asthma Allergy. 2023;16:851–861. https://doi.org/10.2147/JAA.S420328.
7. Banjar SA, Assiri RA, Alshehri GA, Binyousef FH, Alaudah TI, Alawam AS, Aloriney AM. The Impact of Allergic Rhinitis on Asthma and Its Effect on the Quality of Life of Asthmatic Patients. Cureus. 2023;15(3):e35714. https://doi.org/10.7759/cureus.35714.
8. Мизерницкий ЮЛ. Патогенетическое обоснование применения монтелукаста (Синглона) при острых респираторных вирусных инфекциях с бронхообструктивным синдромом у детей раннего и дошкольного возраста. Российский вестник перинатологии и педиатрии. 2020;65(6):129–132. https://doi.org/10.21508/1027-4065-2020-65-6-129-132. Mizernitskiy YuL. Pathogenetic Reasoning for Use of Monteleukast (Singlon) in Acute Respiratory Viral Infections with Broncho-Obstructive Syndrome in Infants and Preschool Age Children. Russian Bulletin of Perinatology and Pediatrics. 2020;65(6):129–132. (In Russ.) https://doi.org/10.21508/10274065-2020-65-6-129-132.
9. Zuberi FF, Haroon MA, Haseeb A, Khuhawar SM. Role of Montelukast in Asthma and Allergic rhinitis patients. Pak J Med Sci. 2020;36(7):1517–1522. https://doi.org/10.12669/pjms.36.7.2657.
10. Krishnamoorthy M, Mohd Noor N, Mat Lazim N, Abdullah B. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis. Drugs. 2020;80(17):1831–1851. https://doi.org/10.1007/s40265-020-01406-9.
11. Diamant Z, Aalders W, Parulekar A, Bjermer L, Hanania NA. Targeting lipid mediators in asthma: time for reappraisal. Curr Opin Pulm Med. 2019;25(1):121–127. https://doi.org/10.1097/MCP.0000000000000544.
12. Jo-Watanabe A, Okuno T, Yokomizo T. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. Int J Mol Sci. 2019;20(14):3580. https://doi.org/10.3390/ijms20143580.
13. Ali O, Szabó A. Review of Eukaryote Cellular Membrane Lipid Composition, with Special Attention to the Fatty Acids. Int J Mol Sci. 2023;24(21):15693. https://doi.org/10.3390/ijms242115693.
14. Dahlke P, Peltner LK, Jordan PM, Werz O. Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators. Front Pharmacol. 2023;14:1219160. https://doi.org/10.3389/fphar.2023.1219160.
15. Goretzki A, Zimmermann J, Rainer H, Lin YJ, Schülke S. Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment – Disease-Specific Findings (Part 1). Curr Allergy Asthma Rep. 2023;23(1):29–40. https://doi.org/10.1007/s11882-022-01057-8.
16. Ni NC, Ballantyne LL, Mewburn JD, Funk CD. Multiple-site activation of the cysteinyl leukotriene receptor 2 is required for exacerbation of ischemia/ reperfusion injury. Arterioscler Thromb Vasc Biol. 2014;34(2):321–330. https://doi.org/10.1161/ATVBAHA.113.302536.
17. Shirasaki H, Kanaizumi E, Himi T. Expression and localization of GPR99 in human nasal mucosa. Auris Nasus Larynx. 2017;44(2):162–167. https://doi.org/10.1016/j.anl.2016.05.010.
18. Peebles RS Jr. Urine: A Lens for Asthma Pathogenesis and Treatment? Am JRespir Crit Care Med. 2021;203(1):1–3. https://doi.org/10.1164/rccm.202007-2899ED.
19. Chan CC, McKee K, Tagari P, Chee P, Ford-H utchinson A. Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur J Pharmacol. 1990;191(3):273–280. https://doi.org/10.1016/0014-2999(90)94159-u.
20. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341(8851):989–990. https://doi.org/10.1016/0140-6736(93)91073-u.
21. Schetters STT, Schuijs MJ. Pulmonary Eosinophils at the Center of the Allergic Space-Time Continuum. Front Immunol. 2021;12:772004. https://doi.org/10.3389/fimmu.2021.772004.
22. Taketomi Y, Murakami M. Regulatory Roles of Phospholipase A2 Enzymes and Bioactive Lipids in Mast Cell Biology. Front Immunol. 2022;13:923265. https://doi.org/10.3389/fimmu.2022.923265.
23. Guimarães M, Vertzoni M, Fotaki N. Performance Evaluation of Montelukast Pediatric Formulations: Part II – a PBPK Modelling Approach. AAPS J. 2022;24(1):27. https://doi.org/10.1208/s12248-021-00662-1.
24. Cingi C, Muluk NB, Ipci K, Şahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015;15(11):64. https://doi.org/10.1007/s11882-015-0564-7.
25. Mullol J, Callejas FB, Méndez-Arancibia E, Fuentes M, Alobid I, Martínez-Antón A et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents. 2010;24(4):403–411. Available at: https://pubmed.ncbi.nlm.nih.gov/21122279/.
26. Lin YC, Huang MY, Lee MS, Hsieh CC, Kuo HF, Kuo CH, Hung CH. Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages. J Microbiol Immunol Infect. 2018;51(1):18–26. https://doi.org/10.1016/j.jmii.2016.04.005.
27. Zhang ZH, Li WX, Wang XM. Effect of intermittent versus daily inhalation of budesonide on pulmonary function and fractional exhaled nitric oxide in children with mild persistent asthma. Zhongguo Dang Dai Er Ke Za Zhi. 2020;22(8): 834–838. (In Chinese) https://doi.org/10.7499/j.issn.1008-8830.2002170.
28. Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. https://doi.org/10.1016/j.jaci.2016.09.028.
29. Pifferi M, Caramella D, Ragazzo V, De Marco E, Pietrobelli A, Boner AL. Montelukast and airway remodeling in children with chronic persistent asthma: an open study. Pediatr Allergy Immunol. 2004;15(5):472–473. https://doi.org/10.1111/j.1399-3038.2004.00184.x.
30. Westergren VS, Wilson SJ, Penrose JF, Howarth PH, Sampson AP. Nasal mucosal expression of the leukotriene and prostanoid pathways in seasonal and perennial allergic rhinitis. Clin Exp Allergy. 2009;39(6):820–828. https://doi.org/10.1111/j.1365-2222.2009.03223.x.
31. Авдеев СН, Геппе НА, Ильина НИ, Демко ИВ, Жестков АВ, Зайцева ОВ и др. Антагонисты лейкотриеновых рецепторов в лечении бронхиальной астмы: согласительный документ «Бронхиальная Астма и антагонисты ЛЕйкоТриеновых рецепторов (БАЛЕТ)». Российский аллергологический журнал. 2023;20(2):130–142. https://doi.org/10.36691/RJA7530. Avdeev SN, Geppe NA, Ilina NI, Demko IV, Zhestkov AV, Zaitseva OV et al. Leukotriene receptor antagonists in the treatment of bronchial asthma: Consensus agreement “Bronchial Asthma and LEukoTriene receptor antagonists (BALET)”. Russian Journal of Allergy. 2023;20(2):130–142. (In Russ.) https://doi.org/10.36691/RJA7530.
32. Rezaeeyan H, Arabfard M, Rasouli HR, Shahriary A, Gh BFNM. Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review. Immun Inflamm Dis. 2023;11(11):e1090. https://doi.org/10.1002/iid3.1090.
33. Wang H, Ji Q, Liao C, Tian L. A systematic review and meta-analysis of loratadine combined with montelukast for the treatment of allergic rhinitis. Front Pharmacol. 2023;14:1287320. https://doi.org/10.3389/fphar.2023.1287320.
34. Мизерницкий ЮЛ, Гаймоленко ИН, Марковская АИ, Потапова НЛ. Клиническая эффективность антилейкотриеновой терапии у детей с острыми бронхитами. Российский вестник перинатологии и педиатрии. 2023;68(1):47–55. https://doi.org/10.21508/1027-4065-2023-68-1-47-55. Mizernitskiy YuL, Gaymolenko IN, Markovskaya AI, Potapova NL. Clinical efficacy of antileukotriene therapy in children with acute bronchitis. Russian Bulletin of Perinatology and Pediatrics. 2023;68(1):47–55. (In Russ.) https://doi.org/10.21508/1027-4065-2023-68-1-47-55.
35. Rochat MK, Illi S, Ege MJ, Lau S, Keil T, Wahn U, von Mutius E. Allergic rhinitis as a predictor for wheezing onset in school-aged children. J Allergy Clin Immunol. 2010;126(6):1170–1175.e2. https://doi.org/10.1016/j.jaci.2010.09.008.
36. Мизерницкий ЮЛ. Бронхообструктивный синдром при ОРИ у детей раннего возраста: расставим точки над «i». В: Мизерницкий ЮЛ (ред.). Пульмонология детского возраста: проблемы и решения. Вып. 18. М.: Медпрактика-М; 2018. С. 108–119. Режим доступа: https://pedklin.ru/upload/book/sbor_pulm_2018.pdf.
37. Grigg J, Nibber A, Paton JY, Chisholm A, Guilbert TW, Kaplan A et al. Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks. J Asthma Allergy. 2018;11:309–321. https://doi.org/10.2147/JAA.S178531.
38. Mikalsen IB, Dalen I, Karlstad Ø, Eide GE, Magnus M, Nystad W, Øymar K. Airway symptoms and atopy in young children prescribed asthma medications: A large-s cale cohort study. Pediatr Pulmonol. 2019;54(10):1557–1566. https://doi.org/10.1002/ppul.24437.
39. Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol. 2018;53(12):1670–1677. https://doi.org/10.1002/ppul.24176.
40. Glockler-Lauf SD, Finkelstein Y, Zhu J, Feldman LY, To T. Montelukast and
41. Neuropsychiatric Events in Children with Asthma: A Nested Case-C ontrol Study. J Pediatr. 2019;209:176–182.e4. https://doi.org/10.1016/j.jpeds.2019.02.009.
42. Dixon EG, Rugg-Gunn CE, Sellick V, Sinha IP, Hawcutt DB. Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review. BMJ Paediatr Open. 2021;5(1):e001206. https://doi.org/10.1136/bmjpo-2021-001206.
43. Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации. М.; 2020. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1.
Review
For citations:
Mizernitskiy YL, Petrova AI. Montelukast: results and prospects for applications in pediatric practice. Meditsinskiy sovet = Medical Council. 2024;(1):82–88. (In Russ.) https://doi.org/10.21518/ms2024-026
Views:
587
Email this article 